Biotechnology company Qlt has announced to acquire Aegerion Pharmaceuticals through its wholly-owned, indirect subsidiary Isotope Acquisition Corp (MergerCo .) to diversify its portfolio of commercialised rare disease programmes.
Pursuant to the acquisition, Isotope Acquisition Corp (MergerCo.) will be merged into Aegerion Pharmaceuticals and serve as a wholly-owned, indirect subsidiary of QLT, which will further be renamed as Novelion Therapeutics.
Greenhill & Co is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal advisor to the acquirer, while JP Morgan Chase & Co is acting as financial advisor and Ropes & Gray LLP is acting as legal advisor to the target company for the transaction.
According to the agreement, Carbylan Therapeutics will be renamed as KalVista Pharmaceuticals and, following the transaction, the existing equity holders of KalVista Pharma will own approximately 81% of the combined company, whereas Carbylan Therapeutics shareholders will own the remaining.
Wedbush PacGrow Life sciences is acting as the advisor and Latham & Watkins LLP is acting as the legal advisor to Carbylan Therapeutics, while Jefferies LLC is acting as advisor and Fenwick & West LLP and Cooley LLP are acting as legal advisors to KalVista Pharma for the transaction.
The acquisition will enable KalVista Pharma to advance the development of its plasma Kallikrein inhibitor platform, hereditary angioedema (HAE) and diabetic macular oedema (DME) programmes and provide patients with much needed treatment.